Five-year overall survival and overall survival by tumor response measures from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

dc.contributor.author	Rimassa, Lorenza
dc.contributor.author	Chan, Stephen
dc.contributor.author	Sangro, Bruno
dc.contributor.author	Varela Calvo, María
dc.contributor.author	(et al.)
dc.date.accessioned	2025-04-30T09:19:00Z
dc.date.available	2025-04-30T09:19:00Z
dc.date.issued	2024
dc.identifier.issn	0270-9139
dc.identifier.issn	1527-3350
dc.identifier.uri	https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2824%2902526-2
dc.identifier.uri	https://hdl.handle.net/10651/78686
dc.language.iso	eng
dc.relation.ispartof	Hepatology
dc.rights	©,
dc.source	WOS:001366004003386
dc.title	Five-year overall survival and overall survival by tumor response measures from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
dc.type	conference output

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.